NGF has previously been implicated as a major mediator of bone pain in a number of diseases, including osteoarthritis, osteosarcoma and prostate cancer, and therapeutics which directly block NGF are undergoing trials for these diseases. Here, NGF is linked to Familial prostate cancer.